̽»¨ÊÓƵ

In August 2013, ̽»¨ÊÓƵ began its first European partnership with Affimed and supported three clinical trials for patients with Hodgkin lymphoma (HL) and Peripheral T-cell Lymphoma (PTCL). Expanding upon the initial work supported by ̽»¨ÊÓƵ TAP, Affimed is currently enrolling "Bispecific NK Engager AFM13 Combined With NK Cells for Patients With Recurrent of Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas." AFM13 is bispecific tetravalent Innate Cell Engager targeting CD30 on tumor cells and CD16A on NK cells and macrophages. 

Affimed is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s proprietary ROCK® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK platform predictably generates customized innate cell engager (ICE®) molecules, which use patients’ immune cells to destroy tumor cells.

̽»¨ÊÓƵ TAP has supported clinical development of AFM13 in several clinical trials that have completed enrollment:

• GHSG-AFM13 An Open-label, Randomized, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma ()
• A Phase 1b Dose Escalation Study to Assess the Safety of AFM13 in Combination With Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma ()
• A Phase II Open-label Multicenter Study to Assess the Efficacy and Safety of AFM13 in Patients With Relapsed or Refractory CD30-positive Peripheral T-cell Lymphoma or Transformed Mycosis Fungoides (REDIRECT, )

Building on the initial work supported by ̽»¨ÊÓƵ TAP and the success of the trials in CD30-positive lymphomas, the company recently completed a trial in partnership with MD Anderson Cancer Center entitled "Bispecific NK Engager AFM13 Combined With NK Cells for Patients With Recurrent of Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas" ().

AFM13 in combination with AB-101 (allogeneic natural killer cells) is currently in a Phase 2 clinical trial in relapsed or refractory Hodgkin lymphoma or CD30-positive PTCL that could eventually lead to commercialization (LuminICE-203, ).

For more information about Affimed, visit .

Recent News

• - announced that the FDA has granted RMAT designation to the combination therapy of acimtamig (AFM13) and AB-101 for the treatment of relapsed or refractory Hodgkin Lymphoma
• - announced oral presentation of phase 1/2 data from AFM13 in combination with NK cells at the 2023 ASH annual meeting
• - announced that the FDA has granted fast track designation to the combination of AFM13 with AlloNK^® for the potential treatment of relapsed/refractory Hodgkin lymphoma
• - announced FDA has cleared IND application for the combination of AFM13 and AB-101 (off-the shelf, non-genetically modified, allogeneic cord blood-derived natural killer cells) to initiate the Phase 2 clinical trial, AFM13-203 (LuminICE-203) in Q3 2023
• - presented final clinical data of AFM13 Phase 2 REDIRECT study in patients with R/R PTCL at the AACR Annual Meeting
• - announced that Affimed remains on track to submit an IND in the first half of 2023 and to initiate a clinical study later in 2023 for the AFM13 and AB-101 co-administered combination therapy in r/r HL and an exploratory arm evaluating the combination in r/r CD30-positive PTCL
• - data update at ASH from the ongoing phase 1/2 study of AFM13 precomplexed with cord blood-derived natural killer (cbNK) cells in patients with CD30-positive relapsed or refractory Hodgkin and Non-Hodgkin lymphomas
• - announced a new strategic partnership to jointly develop, manufacture, and commercialize a combination therapy comprised of Affimed’s Innate Cell Engager AFM13 and Artiva’s cord blood-derived, cryopreserved off-the-shelf allogeneic NK cell product candidate, AB-101